Advertisement

Picture EBD Group Bio-Europe 2017 BEU Berlin Germany November 600x60px
Document › Details

Thermo Fisher Scientific Inc.. (11/4/15). "Press Release: Singapore General Hospital and Thermo Fisher Scientific Collaborate to Identify the Prevalence of Asian-specific Genetic Mutations in Cancer".

Organisations Organisation Thermo Fisher Scientific Inc. (NYSE: TMO)
  Group Thermo Fisher (Group)
  Organisation 2 Singapore General Hospital (SGH)
Products Product Ion Torrent Sequencer (PGM platform)
  Product 2 Oncomine™ Comprehensive Assay (OCA)
Person Person Minotta, Mauricio (Thermo Fisher 201511)
     


Singapore General Hospital (SGH) and Thermo Fisher Scientific today announced the establishment of a collaborative partnership aimed at identifying cancer genetic mutations linked with Asian populations using Thermo Fisher’s Ion Torrent next-generation sequencing (NGS) platform.

The research collaboration will take phased approaches to analyze retrospective samples from cancer patients with Asian ancestry to identify the mutational profiles and their differences from existing data of reference populations, which principally contain data from individuals of Caucasian ancestry.

In the first phase of the project, SGH will perform a validation study using the Ion PGM platform and the Oncomine Comprehensive Assay. The project will then move to NGS-based prospective data analysis of multiple cancers by using formalin fixed paraffin embedded (FFPE) tissues and, potentially, other types of clinical samples. The objective is to realize the highest levels of data acquisition that will lead to new tests with clinical actionability in the future.

"This collaboration with Singapore General Hospital underscores our sustained commitment to serve our global customers in their respective oncology research and clinical communities,” said Mike Nolan, vice president and general manager of oncology for Thermo Fisher Scientific. “We will continue on this path of providing the most advanced tools that add great value in the global effort to manage cancer.”

“Investigating the differences in cancer gene mutations among different populations is an essential factor in advancing healthcare in a multiracial and multicultural society,” said Prof. Tan Puay Hoon, Head, Department of Pathology, SGH. “This partnership will enable the oncology community to take steps toward realizing better and personalized care in the region.”

This research is part of the POLARIS@SingHealth programme funded by A*STAR to enable cutting-edge omics technologies and translate them for disease diagnosis and treatment in Singapore in the future. This will be actualized by establishing the necessary infrastructure and resources, together with its clinical partners.

The project is supported in part by the Central R&D of Thermo Fisher Scientific.

The Ion PGM system and the Oncomine Comprehensive Assay are For Research Use only; Not for use in diagnostic procedures.


About Singapore General Hospital

Singapore General Hospital, a member of Singapore Health Services, is the public sector's flagship hospital. Established in 1821, SGH is Singapore's largest acute tertiary hospital with 1,600 beds and national referral center offering a comprehensive range of 36 clinical specialties on its campus. Every year, about 1 million Singaporeans benefit from advanced medical care delivered by its 800 specialists. As an academic healthcare institution and the bedrock of medical education, SGH plays a key role in nurturing doctors, nurses and allied health professionals, and is committed to innovative translational and clinical research in her continual strive to provide the best care and outcomes to her patients.

www.sgh.com.sg


About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. is the world leader in serving science, with revenues of $17 billion and approximately 50,000 employees in 50 countries. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics and increase laboratory productivity. Through our premier brands – Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific and Unity Lab Services – we offer an unmatched combination of innovative technologies, purchasing convenience and comprehensive support. For more information, please visit www.thermofisher.com.


Contact:

Thermo Fisher Scientific
Mauricio Minotta, 760-929-2456
Mauricio.minotta@thermofisher.com

or

Singapore General Hospital
Carol Ang, +65-6321-4999
carol.ang@sgh.com.sg

   
Record changed: 2016-01-10

Advertisement

Picture EBD Group Bio-Europe 2017 BEU Berlin Germany November 600x60px

More documents for Thermo Fisher (Group)


To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to info@iito.de and simply fill the subject line with the word »MSC newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at Life-Sciences-Germany.com and Life-Sciences-Europe.com

Advertisement

Picture Fairtec GmbH Worldwide Event Solutions 600x60px




» top

Advertisements

Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture EBD Group Bio-Europe 2017 BEU Berlin Germany November 120x80px Picture Eurasanté BioFIT 2017 Strasbourg France November 120x80px Picture EBD Group Bio-Europe 2017 BEU Berlin Germany November 120x80px Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px Banner Fairtec GmbH Solutions for Smarter Business Events Exhibitions 120x120px Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture Eurasanté BioFIT 2017 Strasbourg France November 120x80px Picture EBD Group Bio-Europe 2017 BEU Berlin Germany November 120x80px